BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

The following is a summary of “Can self-testing be enhanced to hasten safe return of healthcare workers in pandemics? Random ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...

State of play: Currently, providers can make educated guesses about how sick a patient might get from COVID based on ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

COVID-19 spreads from an infected person to others through respiratory droplets and aerosols that can vary in size, such as: large droplets that fall to the ground rapidly (within seconds or minutes) ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially ...

It provides a more precise prediction than currently available of how serious the case is by focusing on autoantibodies in ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...